Abstract
Perennial allergic rhinitis (PAR) can have a significant impact on a patient's quality of life. While allergen avoidance is the first line of management for PAR, complete avoidance is difficult. Therapeutic options available for PAR include intranasal corticosteroids (INS), H1-antihistamines, decongestants and local chromones, as well as immunotherapy. For mild symptoms, INS and antihistamines are the standard of care, whereas for moderate-to-severe PAR, INS are the preferred therapy due to their proven efficacy. Patient quality of life and therapy preference play a role in maintaining adherence to treatment.
Key Points
* Several classes of pharmacologic agents are available for the treatment of perennial allergic rhinitis (PAR), including intranasal corticosteroids (INS), H1- antihistamines, local chromones and decongestants.
* Intranasal corticosteroids are the first-line option in moderate-to-severe PAR and can also be used in mild PAR, due to their proven efficacy.
* Second-generation oral antihistamines are effective at controlling mild-to-moderate PAR, have a fast onset of action and good safety profiles.
* Oral decongestants, usually in combination with oral antihistamines, are recommended for mild nasal congestion and as add-on therapy to INS for moderate-to-severe nasal congestion. Intranasal decongestants can also be used in severe cases of blockage.
* Local chromones are available as intranasal formulations for reducing the nasal symptoms of PAR, particularly in children.
* Successful treatment of PAR requires long-term treatment and patient adherence. Therefore, patient quality of life and patient preference for an agent should be considered when choosing a therapeutic option.
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Sibbald B. Epidemiology of allergic rhinitis. In: Burr ML, ed.Epidemiology of Clinical Allergy. Monographs in Allergy, Vol 31.Basel, Karger, 1993, pp 61–79.
2. Meltzer EO. The prevalence and medical and economic impact of allergic rhinitis in the United States.J Allergy Clin Immunol1997;99(6 Pt 2):S805–S828.
3. Smart B. The costs of asthma and allergy.American Academy of Allergy, Asthma, and Immunology.Available at:http://www.aaaai.org/patients/advocate/2004/fall/costs.stm. Accessed May 19, 2005.
4. Thompson AK, Juniper E, Meltzer EO. Quality of life in patients with allergic rhinitis.Ann Allergy Asthma Immunol2000;85:338–347.
5. Reilly MC, Tanner A, Meltzer EO. Work, classroom and activity impairment instruments: validation studies in allergic rhinitis.Clin Drug Invest1996;11:278–288.
6. Meltzer E, Nathan R, Selner J, et al. Quality of life and rhinitis symptoms: Results of a nationwide survey with the SF-36 and RQLQ questionnaire.J Allergy Clin Immunol1997;99:S815–S819.
7. Vuurman EF, van Veggel LM, Uiterwijk MM. Seasonal allergic rhinitis and antihistamine effects on children's learning.Ann Allergy1993;71:121–126.
8. Settipane RA. Complications of allergic rhinitis.Allergy Asthma Proc1999 20:209–213.
9. Spector S. Overview of comorbid associations of allergic rhinitis.J Allergy Clin Immunol1997;99:S773–S780.
10. Slavin R. Sinusitis in adults and its relation to allergic rhinitis, asthma, and nasal polyps.J Allergy Clin Immunol1988;82:950–956.
11. Bousquet J, van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma.J Allergy Clin Immunol2001;108(Suppl 5):S147–S334.
12. Corey JP, Adham RE, Abbass AH, et al. The role of IgE-mediated hypersensitivity in otitis media with effusion.Am J Otolaryngol1994;15:138–144.
13. International consensus report on the diagnosis and management of rhinitis. International rhinitis management working group.Allergy. 1994;49(19 Suppl):1–34.
14. Ciprandi G, Cirillo I, Vizzaccaro A, et al. Seasonal and perennial allergic rhinitis: is this classification adherent to real life?Allergy2005;60:882–887.
15. Bucholtz GA, Lockey RF, Wunderlin RP, et al. A three-year aerobiologic pollen survey of the Tampa Bay area, Florida.Ann Allergy1991;67:534–540.
16. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis.J Allergy Clin Immunol2001;108(1 Suppl):S2–S8.
17. Quillen DM, Feller DB. Diagnosing rhinitis: allergic vs. nonallergic.Am Fam Physician2006;73:1583–1590.
18. Slavin RG. Occupational rhinitis.Ann Allergy Asthma Immunol1999; 83(6 Pt 2):597–601.
19. Agency for Healthcare Research and Quality. Evidence report/technology assessment No. 54. Management of allergic and nonallergic rhinitis. May, 2002.
20. Gendo K, Larson EB. Evidence-based diagnostic strategies for evaluating suspected allergic rhinitis.Ann Intern Med2004;140:278–289.
21. Hamilton RG, Adkinson NF Jr 23. Clinical laboratory assessment of IgE-dependent hypersensitivity.J Allergy Clin Immunol2003;111(2 Suppl):S687–S701.
22. Johansson SG. ImmunoCAP Specific IgE test: an objective tool for research and routine allergy diagnosis.Expert Rev Mol Diagn2004;4:273–279.
23. Sibbald B, Barnes G, Durham SR. Skin prick testing in general practice: a pilot study.J Adv Nurs1997;26:527–542.
24. Lebel B, Bousquet J, Morel A, et al. Correlation between symptoms and the threshold for release of mediators in nasal secretions during nasal challenge with grass-pollen grains.J Allergy Clin Immunol1988;82(5 Pt 1):869–877.
25. Naclerio RM, Meier HL, Kagey-Sobotka A, et al. Mediator release after nasal airway challenge with allergen.Am Rev Respir Dis1983 128:597–602.
26. Pawankar R, Yamagishi S, Yagi T. Revisiting the roles of mast cells in allergic rhinitis and its relation to local IgE synthesis.Am J Rhinol2000;14:309–317.
27. White M. Mediators of inflammation and the inflammatory process.J Allergy Clin Immunol1999;103(3 Pt 2):S378–S381.
28. Wang DY, Clement P. Pathogenic mechanisms underlying the clinical symptoms of allergic rhinitis.Am J Rhinol2000;14:325–333.
29. Carswell F, Oliver J, Weeks J. Do mite avoidance measures affect mite and cat airborne allergens?Clin Exp Allergy1999;29:193–200.
30. Vaughan JW, McLaughlin TS, Perzanowski MS, et al. Evaluation of materials used for bedding encasement: Effect of pore size in blocking cat and dust mite allergen.J Allergy Clin Immunol1999;103:227–231.
31. Arshad SH, Bojarskas J, Tsitoura S, et al. Prevention of sensitization to house dust mite by allergen avoidance in school age children: a randomized controlled study.Clin Exp Allergy2002;32:843–849.
32. Moon JS, Choi SO. Environmental controls in reducing house dust mites and nasal symptoms in patients with allergic rhinitis.Yonsei Med J1999;40:238–243.
33. Terreehorst I, Hak E, Oosting AJ, et al. Evaluation of impermeable covers for bedding in patients with allergic rhinitis.N Engl J Med2003;349:237–246.
34. Woodfolk JA, Luczynska CM, de Blay F. The effect of vacuum cleaners on the concentration and particle size distribution of airborne cat allergen.J Allergy Clin Immunol1993 91:829–837.
35. Wood RA, Johnson EF, Van Natta ML, et al. A placebo-controlled trial of a HEPA air cleaner in the treatment of cat allergy.Am J Respir Crit Care Med1998;158:115–120.
36. Davies MJ, Fisher LH, Chegini S, et al. A practical approach to allergic rhinitis and sleep disturbance management.Allergy Asthma Proc2006;27:224–230.
37. Van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis.Allergy2000;55:116–134.
38. International consensus report on the diagnosis and managnment of rhinitis. International rhinitis managment working group.Allergy1994;49:1–34.
39. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology.Ann Allergy Asthma Immunol1998;81(5 Pt 2):478–518.
40. Pujols L, Mullol J, Torrego A, et al. Glucocorticoid receptors in human airways.Allergy2004;59:1042–1052.
41. Mullol J, Xaubet A, Lopez E, et al.Comparative study of the effects of different glucocorticosteroids on eosinophil survival primed by cultured epithelial cell supernatants obtained from nasal mucosa and nasal polyps.Thorax1995;50:270–274.
42. Mullol J, Lopez E, Roca-Ferrer J, et al. Effects of topical anti-inflammatory drugs on eosinophil survival primed by epithelial cells. Additive effect of glucocorticoids and nedocromil sodium.Clin Exp Allergy1997;27:1432–1441.
43. Sim TC, Reece LM, Hilsmeier KA, et al. Secretion of chemokines and other cytokines in allergen-induced nasal responses: inhibition by topical steroid treatment.Am J Respir Crit Care Med1995;152:927–933.
44. Pipkorn U, Proud D, Lichtenstein LM, et al. Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticosteroids.N Engl J Med1987;316:1506–1510.
45. Scadding GK, Darby YC, Austin CE. Effect of short-term treatment with fluticasone propionate nasal spray on the response to nasal allergen challenge.Br J Clin Pharmacol1994;38:447–451.
46. Wang D, Smitz J, De Waele M, et al. Effect of topical applications of budesonide and azelastine on nasal symptoms, eosinophil count and mediator release in atopic patients after nasal allergen challenge during the pollen season.Int Arch Allergy Immunol1997;114:185–192.
47. Cervin A, Andersson M. Intranasal steroids and septum perforation–an overlooked complication? A description of the course of events and a discussion of the causes.Rhinology1998;36:128–132.
48. Holm AF, Fokkens WJ, Godthelp T, et al. A 1-year placebo-controlled study of intranasal fluticasone propionate aqueous nasal spray in patients with perennial allergic rhinitis: a safety and biopsy study.Clin Otolaryngol1998;23:69–73.
49. Wilson AM, McFarlane LC, Lipworth BJ. Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity.J Allergy Clin Immunol1998;101(4 Pt 1):470–474.
50. Wilson AM, Sims EJ, McFarlane LC, et al. Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitis.J Allergy Clin Immunol1998;102(4 Pt 1):598–604.
51. Wilson AM, Lipworth BJ. 24 hour and fractionated profiles of adrenocortical activity in asthmatic patients receiving inhaled and intranasal corticosteroids.Thorax1999;54:20–26.
52. Cave A, Arlett P, Lee E. Inhaled and nasal corticosteroids: factors affecting the risks of systemic adverse effects.Pharmacol Ther1999;83:153–179.
53. Skoner DP, Rachelefsky GS, Meltzer EO, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate.Pediatrics2000;105:E23.
54. Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray.Pediatrics2000;105:E22.
55. Bisgaard H, Allen D, Milanowski J, et al. Twelve-month safety and efficacy of inhaled fluticasone propionate in children aged 1 to 3 years with recurrent wheezing.Pediatrics2004;113:e87–94.
56. Ober S, Gentile D, Kairis E, et al. Growth velocity and HPA axis function during 1-year treatment with triamcinolone acetonide aqueous (TAA) nasal spray in children with allergic rhinitis.J Allergy Clin Immunol2005;115:1064.–
57. Skoner DP, Gentile D, Angelini B, et al. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis.Ann Allergy Asthma Immunol2003;90:56–62.
58. Lumry WR. A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis.J Allergy Clin Immunol1999;104(4 Pt 1):S150–S158.
59. Mandl M, Nolop K, Lutsky BN. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. The 194-079 Study Group.Ann Allergy Asthma Immunol1997;79:237–245.
60. Berger WE, Kaiser H, Gawchik SM, et al. Triamcinolone acetonide aqueous nasal spray and fluticasone propionate are equally effective for relief of nasal symptoms in patients with seasonal allergic rhinitis.Otolaryngol Head Neck Surg2003;129:16–23.
61. Bousquet J, Bullinger M, Fayol C, et al. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire.J Allergy Clin Immunol1994;94(2 Pt 1):182–188.
62. Tripathi A, Patterson R. Impact of allergic rhinitis treatment on quality of life.Pharmacoeconomics2001;19:891–899.
63. Potter PC, Van Niekerk CH, Schoeman HS. Effects of triamcinolone on quality of life in patients with persistent allergic rhinitis.Ann Allergy Asthma Immunol2003;91:368–374.
64. Ciprandi G, Canonica WG, Grosclaude M, et al. Effects of budesonide and fluticasone propionate in a placebo-controlled study on symptoms and quality of life in seasonal allergic rhinitis.Allergy2002;57:586–591.
65. Mintz M, Garcia J, Diener P, et al. Triamcinolone acetonide aqueous nasal spray improves nocturnal rhinitis-related quality of life in patients treated in a primary care setting: the Quality of Sleep in Allergic Rhinitis study.Ann Allergy Asthma Immunol2004;92:255–261.
66. Loh CY, Chao SS, Chan YH, et al. A clinical survey on compliance in the treatment of rhinitis using nasal steroids.Allergy2004;59:1168–1172.
67. Bachert C, El-Akkad T. Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis.Ann Allergy Asthma Immunol2002;89:292–297.
68. Shah S, Mahadevia PJ, Lelbman C, et al. Patient preferences and willingness to adhere to intranasal corticosteroids: a conjoint analysis in allergic rhinitis.Ann Allergy Asthma Immunol2005;94:192 (P240).
69. Gerson I, Green L, Fishken D. Patient preference and sensory comparisons of nasal spray allergy medications.J Sens Stud1999;14:491–496.
70. Shah SR, Miller C, Pethick N, et al. Two multicenter, randomized, single-blind, single-dose, crossover studies of specific sensory attributes of budesonide aqueous nasal spray and fluticasone propionate nasal spray.Clin Ther2003;25:2198–2214.
71. Meltzer EO, Bardelas J, Goldsobel A, et al. A preference evaluation study comparing the sensory attributes of mometasone furoate and fluticasone propionate nasal sprays by patients with allergic rhinitis.Treat Respir Med2005;4:289–296.
72. Babe KS, Serafin WE. Histamine, bradykinin, and their antagonists. In: Hardman JG, Limbird LE, Molinoff PB, et al eds.Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed. New York, McGraw-Hill,1996, pp 581–600.
73. Shamsi Z, Hindmarch I. Sedation and antihistamines: a review of inter-drug differences using proportional impairment ratios.Hum Psychopharmacol2000;15:S3–S30.
74. Ratner PH, Findlay SR, Hampel F Jr, et al. A double-blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis.J Allergy Clin Immunol1994;94:818–825.
75. Schata M, Jorde W, Richarz-Barthauer U. Levocabastine nasal spray better than sodium cromoglycate and placebo in the topical treatment of seasonal allergic rhinitis.J Allergy Clin Immunol1991;87:873–878.
76. Bruttmann G, Charpin D, Germouty J, et al. Evaluation of the efficacy and safety of loratadine in perennial allergic rhinitis.J Allergy Clin Immunol1989;83(2 Pt 1):411–416.
77. Mansmann HC Jr, Altman RA, Berman BA, et al. Efficacy and safety of cetirizine therapy in perennial allergic rhinitis.Ann Allergy1992;68:348–353.
78. Simons FE, Prenner BM, Finn A Jr. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis.J Allergy Clin Immunol2003;111:617–622.
79. Lee DK, Gray RD, Robb FM, et al. A placebo-controlled evaluation of butterbur and fexofenadine on objective and subjective outcomes in perennial allergic rhinitis.Clin Exp Allergy2004;34:646–649.
80. Casale TB, Blaiss MS, Gelfand E, et al. First do no harm: managing antihistamine impairment in patients with allergic rhinitis.J Allergy Clin Immunol2003;111:S835–S842.
81. Day J, Briscoe M, Welsh A, et al. Onset of action, efficacy and safety of a new antihistamine (fexfenadine HCl) using controlled antigen exposure in an environmental exposure unit (EEU).Clinical Investigations in Medicine1996;19:S4 (Abs 9).
82. Day JH, Briscoe M, Rafeiro E, et al. Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system.Ann Allergy Asthma Immunol2001;87:474–481.
83. Sussman G, Mason J, Compton D, et al. The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis.J Allergy Clin Immunol1999;104:100–106.
84. Grosclaude M, Mees K, Pinelli ME, et al. Cetirizine and pseudoephedrine retard, given alone or in combination, in patients with seasonal allergic rhinitis.Rhinology1997;35:67–73.
85. Bronsky E, Boggs P, Findlay S, et al. Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis.J Allergy Clin Immunol1995;96:139–147.
86. Pleskow W, Grubbe R, Weiss S, et al. Efficacy and safety of an extended-release formulation of desloratadine and pseudoephedrine vs the individual components in the treatment of seasonal allergic rhinitis.Ann Allergy Asthma Immunol2005;94:348–354.
87. Allergen immunotherapy: a practice parameter. American Academy of Allergy, Asthma and Immunology. American College of Allergy, Asthma and Immunology.Ann Allergy Asthma Immunol2003;90(1 Suppl):1–40.
88. Malling HJ. Immunotherapy as an effective tool in allergy treatment.Allergy1998;53:461–472.
89. Borchers AT, Keen CL, Gershwin ME. Fatalities following allergen immunotherapy.Clin Rev Allergy Immunol2004;27:147–158.
90. Berger WE. Treatment of allergic rhinitis and other immunoglobulin E-mediated diseases with anti-immunoglobulin E antibody.Allergy Asthma Proc2006;27(2 Suppl 1):S29–32.
91. Belliveau PP. Omalizumab: a monoclonal anti-IgE antibody.MedGenMed2005;7:27.
